Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | SLC5A2 | P31639 | 18/20 | 0.39 |
| ▸ | SLC5A1 | P13866 | 5/20 | 0.37 |
| ▸ | CA12 | O43570 | 1/20 | 0.35 |
| ▸ | CA1 | P00915 | 1/20 | 0.35 |
| ▸ | CA2 | P00918 | 1/20 | 0.35 |
| ▸ | CA9 | Q16790 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18511214 | 1.00 | TSHR (0.41) | TSHRSLC5A2SLC5A1CA12CA1 | |
| SCHEMBL18511218 | 1.00 | TSHR (0.41) | TSHRSLC5A2SLC5A1CA12CA1 | |
| SCHEMBL10228169 | 0.94 | TSHR (0.49) | TSHRSLC5A2CA12CA1CA2 | |
| SCHEMBL15030983 | 0.94 | TSHR (0.49) | TSHRSLC5A2CA12CA1CA2 | |
| SCHEMBL16730398 | 0.94 | TSHR (0.49) | TSHRSLC5A2CA12CA1CA2 | |
| SCHEMBL29657483 | 0.94 | TSHR (0.49) | TSHRSLC5A2CA12CA1CA2 | |
| SCHEMBL14644615 | 0.94 | TSHR (0.49) | TSHRSLC5A2CA12CA1CA2 | |
| SCHEMBL1670038 | 0.94 | TSHR (0.49) | TSHRSLC5A2CA12CA1CA2 | |
| SCHEMBL16730393 | 0.94 | TSHR (0.49) | TSHRSLC5A2CA12CA1CA2 | |
| SCHEMBL18522415 | 0.87 | SLC5A2 (0.40) | SLC5A2SLC5A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8466114-B2 | Glycoside derivatives and uses thereof | NOVARTIS AG (CH) | 2013-06-18 | — | — | US | disclosed |
| US-20120178680-A1 | GLYCOSIDE DERIVATIVES AND USES THEREOF | NOVARTIS AG (CH) | 2012-07-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120178680-A1 | GLYCOSIDE DERIVATIVES AND USES THEREOF | SLC5A1, SLC5A2, SLC2A1 | TSHR 4409/4885SLC5A2 2/4885SLC5A1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.